EA200900212A1 - Элементы нуклеиновых кислот, обладающие регуляторной функцией - Google Patents

Элементы нуклеиновых кислот, обладающие регуляторной функцией

Info

Publication number
EA200900212A1
EA200900212A1 EA200900212A EA200900212A EA200900212A1 EA 200900212 A1 EA200900212 A1 EA 200900212A1 EA 200900212 A EA200900212 A EA 200900212A EA 200900212 A EA200900212 A EA 200900212A EA 200900212 A1 EA200900212 A1 EA 200900212A1
Authority
EA
Eurasian Patent Office
Prior art keywords
elements
gene
well
expression
sequence
Prior art date
Application number
EA200900212A
Other languages
English (en)
Other versions
EA016880B1 (ru
Inventor
Барбара Эненкель
Керстин Зауттер
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200900212A1 publication Critical patent/EA200900212A1/ru
Publication of EA016880B1 publication Critical patent/EA016880B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны последовательности ДНК, прежде всего усиливающие транскрипцию или экспрессию элементы (ТЕ-элементы), а также их применение в экспрессионном векторе в сочетании с энхансером, промотором, геном продукта и селектируемым маркером. В заявке описаны также последовательность SEQ ID NO: 1, а также ТЕ-элементы ТЕ-01, -02, -03, -04, -06, -07, -08, -10, -11 или -12. Наиболее предпочтительными являются ТЕ-06, ТЕ-07 или ТЕ-08, что обусловлено их небольшим размером. Последовательность NO: 1 выведена из области последовательности, расположенной против хода транскрипции относительно кодирующей области гена Ub/S27a из СНО-клеток. ТЕ-элементы вызывают усиление экспрессии гена продукта при стабильной интеграции в эукариотический геном, предпочтительно геном CHO-DG44-клетки. Это позволяет преодолевать хромосомальные позиционные воздействия, защищать от них или устранять их. В результате этого достигается повышение доли высокопродуктивных клеток в трансфектированной смеси, а также абсолютного уровня экспрессии вплоть до 15 раз.
EA200900212A 2006-07-26 2007-06-15 Элементы нуклеиновых кислот, обладающие регуляторной функцией EA016880B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117862 2006-07-26
PCT/EP2007/055954 WO2008012142A1 (de) 2006-07-26 2007-06-15 Regulatorische nukleinsäureelemente

Publications (2)

Publication Number Publication Date
EA200900212A1 true EA200900212A1 (ru) 2009-10-30
EA016880B1 EA016880B1 (ru) 2012-08-30

Family

ID=37441548

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900212A EA016880B1 (ru) 2006-07-26 2007-06-15 Элементы нуклеиновых кислот, обладающие регуляторной функцией

Country Status (23)

Country Link
US (3) US20080124760A1 (ru)
EP (1) EP2049671B1 (ru)
JP (1) JP5270544B2 (ru)
KR (1) KR101485853B1 (ru)
CN (1) CN101517085B (ru)
AR (1) AR061472A1 (ru)
AU (1) AU2007278368B2 (ru)
BR (1) BRPI0714594A2 (ru)
CA (1) CA2658595C (ru)
CY (1) CY1113711T1 (ru)
DK (1) DK2049671T3 (ru)
EA (1) EA016880B1 (ru)
ES (1) ES2401654T3 (ru)
HK (1) HK1134107A1 (ru)
IL (1) IL196676A0 (ru)
MX (1) MX2009000781A (ru)
NO (1) NO20090057L (ru)
NZ (1) NZ575115A (ru)
PL (1) PL2049671T3 (ru)
PT (1) PT2049671E (ru)
SI (1) SI2049671T1 (ru)
TW (1) TW200815591A (ru)
WO (1) WO2008012142A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
KR101993938B1 (ko) 2011-04-13 2019-06-27 내셔날 리서치 카운실 오브 캐나다 IFNα2로부터의 SAR 인자를 갖는 발현 시스템
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP6728053B2 (ja) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド 抗mcam抗体及び関連する使用方法
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
RS61924B1 (sr) * 2015-02-02 2021-06-30 Meiragtx Uk Ii Ltd Regulacija genske ekspresije putem aptamerom posredovane modulacije alternativnog splajsovanja
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
CA3117816A1 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
JP7412860B2 (ja) 2020-10-16 2024-01-15 株式会社奥村組 泥水式シールド掘進機および泥水式シールド掘進機における圧縮空気の圧力調整方法
AU2022261882A1 (en) * 2021-04-21 2023-12-07 Janssen Biotech, Inc. Materials and methods for improved phosphotransferases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp Bifunktionelle wählbare fusionsgene
US5786166A (en) 1991-10-25 1998-07-28 University Of Tennessee Research Corporation Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
DK0873405T3 (da) * 1996-01-11 2005-01-17 Immunex Corp Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer
WO2000034319A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034326A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034325A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
AUPP967999A0 (en) * 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
ES2257303T3 (es) 1999-07-12 2006-08-01 Genentech, Inc. Vectores de expresion y procedimientos.
EP1305412A2 (en) 1999-10-14 2003-05-02 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
DE60235616D1 (de) 2001-04-05 2010-04-22 Millipore Corp Gesteigerte genexpression
PT1600510E (pt) 2001-07-04 2007-06-25 Chromagenics Bv Sequências de adn com actividade anti-repressora.
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen

Also Published As

Publication number Publication date
AR061472A1 (es) 2008-08-27
HK1134107A1 (en) 2010-04-16
AU2007278368A1 (en) 2008-01-31
ES2401654T3 (es) 2013-04-23
JP5270544B2 (ja) 2013-08-21
CN101517085B (zh) 2013-08-07
SI2049671T1 (sl) 2013-04-30
PT2049671E (pt) 2013-01-24
US9045776B2 (en) 2015-06-02
US20150337333A1 (en) 2015-11-26
JP2009544293A (ja) 2009-12-17
EP2049671B1 (de) 2012-12-19
KR101485853B1 (ko) 2015-01-23
IL196676A0 (en) 2011-08-01
TW200815591A (en) 2008-04-01
CA2658595C (en) 2016-05-31
EP2049671A1 (de) 2009-04-22
KR20090046887A (ko) 2009-05-11
CN101517085A (zh) 2009-08-26
WO2008012142A1 (de) 2008-01-31
EA016880B1 (ru) 2012-08-30
CA2658595A1 (en) 2008-01-31
US20100311121A1 (en) 2010-12-09
BRPI0714594A2 (pt) 2013-02-19
US20080124760A1 (en) 2008-05-29
US9708626B2 (en) 2017-07-18
AU2007278368B2 (en) 2013-12-19
CY1113711T1 (el) 2016-06-22
NO20090057L (no) 2009-02-16
PL2049671T3 (pl) 2013-05-31
MX2009000781A (es) 2009-01-29
NZ575115A (en) 2011-10-28
DK2049671T3 (da) 2013-04-08

Similar Documents

Publication Publication Date Title
EA200900212A1 (ru) Элементы нуклеиновых кислот, обладающие регуляторной функцией
Sun et al. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown
ES2541771T3 (es) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
ATE404679T1 (de) Neue expressionsvektoren
DE602004031041D1 (de) In pflanzenplastiden funktionsfähiger promotor
EA200801462A1 (ru) Связывающий днк-сайт активатора транскрипции, пригодный для экспрессии генов
PL1687435T3 (pl) Odporność na owady z użyciem hamowania ekspresji genów
JP2006149395A5 (ru)
JP2013505013A5 (ru)
MX350551B (es) Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas que expresan los mismos y metodos para usarlos.
WO2003012054A3 (en) Methods and compositions relating to improved lentiviral vector production systems
WO2006013103A3 (de) Induzierbare genexpression
ATE510920T1 (de) Dna-sequenzen zur regulation der transkription
Khavinson et al. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression
BR0209551A (pt) Promotor de gene especìfico de folha de café
NZ591439A (en) pCAGGS VECTOR COMPRISING AN 829 BASE PAIR DELETION IN THE CHICKEN-BETA ACTIN INTRON WHICH RESULTS IN ENHANCED EXPRESSION OF A GENE OF INTEREST
RU2012130149A (ru) Векторная система на основе aslv
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
MXPA05011774A (es) Gen de factor de transcripcion inducido por condiciones de deficit de agua y acido abscisico a partir de helianthus annuus, promotor y plantas transgenicas.
DK1222294T3 (da) Promotor til regulering af ekspression af fremmede gener
CA2429451A1 (en) Isolated luciferases and their use
JP4719670B2 (ja) N−myc発現腫瘍におけるヒトN−myc遺伝子のアンチセンスおよびアンチジーンペプチド核酸(PNA)による選択的阻害法
EA200500873A1 (ru) Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита
Chawsheen et al. SRXN1 (sulfiredoxin 1)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU